3 Horrendous Healthcare Stocks This Week 2-28-14


Published on

3 of the most horrendous stocks in the world of healthcare this week.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-affymetrix-inc-shares-dropped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • 3 Horrendous Healthcare Stocks This Week 2-28-14

    1. 1. 3 Horrendous Health-Care Stocks This Week
    2. 2. The shortest month of the year is now over, but the last week of February proved to be a long one for these three horrendous health-care stocks.
    3. 3. Ampio Pharmaceuticals (Nasdaq: AMPE) The stock of the biopharmaceutical firm focusing on antiinflammatory drugs plunged nearly 21% for the week.
    4. 4. Why Ampio tanked • The company announced a secondary public offering of 8.5 million shares at $7 per share. • That amount was well below the current share price -- leading to the sharp drop. • Ampio plans to use the added cash in part to complete clinical trials for anti-inflammatory drug Ampion and diabetic macular edema drug Optina.
    5. 5. Questcor Pharmaceuticals (Nasdaq: QCOR) Shares of the biotech plunged more than 20% this week.
    6. 6. Why Questcor investors were quaking • A damaging report was published online by Citron Research. • Citron alleged that lab results of samples of Questcor’s primary drug, Acthar, contained little to none of its primary active ingredient, ACTH. • The FDA received Citron’s research and said the lab findings warrant an investigation. • The allegations overshadowed another solid earnings performance from Questcor announced this week.
    7. 7. Aegerion Pharmaceuticals (Nasdaq: AEGR) The stock of the biopharmaceutical company fell nearly 18% this week.
    8. 8. Why Aegerion shareholders were agitated • The company posted a Q4 loss of $0.47 per share -- worse than the expected $0.30-per-share loss. • Juxtapid generated $24.5 million in net product sales for the quarter, but analysts estimated revenue a tad higher at $24.9 million. • Aegerion’s full-year guidance of $190 million to $210 million in net product revenue was in the expected range but possibly disappointed investors wanting higher growth.
    9. 9. Best shot at bouncing back? • Questcor could very well rebound, but it’s best to wait for the questions to be resolved. • In my view, Aegerion has a great drug but needs to generate higher growth to justify its valuation. • Ampio’s secondary offering dilutes available shares by around 8% -- well below the 21% drop this week. • Because of this and the potential for its pipeline drugs, Ampio gets the nod for the best shot at bouncing back.
    10. 10. Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!